845519-27-9Relevant academic research and scientific papers
Mapping the catechol binding site in dopamine D1 receptors: Synthesis and evaluation of two parallel series of bicyclic dopamine analogues
Bonner, Lisa A.,Laban, Uros,Chemel, Benjamin R.,Juncosa, Jose I.,Lill, Markus A.,Watts, Val J.,Nichols, David E.
experimental part, p. 1024 - 1040 (2012/01/06)
A novel class of isochroman dopamine analogues, originally reported by Abbott Laboratories, have >100-fold selectivity for D1-like over D2-like receptors. We synthesized a parallel series of chroman compounds and showed that repositioning the oxygen atom in the heterocyclic ring decreases potency and confers D2-like receptor selectivity to these compounds. Insilico modeling supports the hypothesis that the altered pharmacology for the chroman series is due to potential intramolecular hydrogen bonding between the oxygen in the chroman ring and the meta-hydroxy group of the catechol moiety. This interaction realigns the catechol hydroxy groups and disrupts key interactions between these ligands and critical serine residues in TM5 of the D1-like receptors. This hypothesis was tested by the synthesis and pharmacological evaluation of a parallel series of carbocyclic compounds. Our results suggest that if the potential for intramolecular hydrogen bonding is removed, D1-like receptor potency and selectivity are restored. What a difference an H bond makes: Structurally related chromans, isochromans, and their carbocyclic analogues were assessed for dopamine D1 and D2 receptor affinity. Isochromans and carbocyclic analogues had high D1 receptor affinity. Poor affinity for the chromans was attributed to an intramolecular hydrogen bond, which disrupts the ligand-receptor hydrogen bonding network.
Facile synthesis of octahydrobenzo[h]isoquinolines: Novel and highly potent D1 dopamine agonists
Bonner, Lisa A.,Chemel, Benjamin R.,Watts, Val J.,Nichols, David E.
experimental part, p. 6763 - 6770 (2010/10/20)
The octahydrobenzo[h]isoquinoline scaffold is of interest as a conformationally-restricted phenethylamine that may be useful for constructing biologically active products. Surprisingly, however, no tractable synthesis of this ring system has been reported
OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR
-
Page/Page column 30, (2010/11/05)
Octahydrobenzoisoquinoline modulators of dopamine receptors are described herein. Methods for using octahydrobenzoisoquinoline modulators of dopamine receptors in the treatment of dopamine dysfunction are also described herein.
